reiter market outperform rate price target
corpor base discount earn per share revenu multipl
analysi yesterday report financi result provid
key corpor pipelin updat well financi guidanc
continu highlight investor solid revenu perform ruxolitinib rux
across multipl indic well grow late-stag pipelin multipl
mileston expect year rux expect gener sale
pemigatinib obtain prioriti review may pdufa data
novarti nv nc file sr-agvhd world-wid posit phase result
come compani dermatolog franchis post-tafasitamab cash
posit pro forma believ repres uniqu invest
opportun whose share attract price potenti downsid bear
case potenti upsid bull case
itacitinib least model tafasitamab
fail achiev primari endpoint lower
probabl success itacitinib sn-agvhd well sn-
cgvhd even though could still potenti succeed see
note detail result loss estim revenu
off-set howev subsequ inclus risk-adjust
revenu tafasitamab dlbcl cll follow incyt collabor
licens agreement morphosi mor mo pt butler prior
remov itacitinib base case scenario estim
drug would account total product revenu contrast
estim tafasitamab could account incyt
product revenu taken togeth believ compani mid-term revenu
prospect stronger failur
nda submit pemigatinib capmatinib expect compani
file pemigatinib nda fda breakthrough therapi
design believ pemigatinib approv second-lin
cholangiocarcinoma cca could act wedg fgfr-driven tumor
potenti open door futur approv front-lin cca second-
front-lin bladder cancer fgfr tumor agnost indic recent
also announc fda accept nda capmatinib
mutat advanc non-smal cell lung cancer nsclc prioriti
review estim capmatinib could achiev peak risk-adjust revenu
 alon receiv royalti
set stage dermatolog throughout earli
incyt dermatolog franchis matur posit phase ii result
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
rux cream vitiligo present eadv confer see note
posit top-lin result phase trial rux cream mild
moder ad see note posit top-lin result partner eli
lilli nc phase baricitinib trial moder sever ad breeze-
expect top-lin result
nda submiss rux cream ad
full trial result scientif meet initi result
phase true-v trial rux cream vitiligo expect
full result present annual meet european societi
blood marrow transplant ebmt abstract provid addit detail
novarti announc rux met primari endpoint superior orr day
compar best avail therapi bat sr-agvhd back octob see note
detail avail abstract accept upcom ebmt meet march
rux achiev impress statist signific improv orr day
compar bat durabl orr day compar
bat figur rux also show lower probabl loss respons figur respect
safeti rux bat arm similar patient rux arm experienc
grade day compar bat arm remind rux approv
 sr-agvhd may result expect support ex-u
registr eu japan canada switzerland etc novarti
figur loss respons
continu data expect
follow interim efficaci safeti analysi trial sr-cgvhd
allow continu without modif base previou convers
manag dmc look unblind data patient complet six-
month follow-up although would nice interim efficaci met trial
stop earli import keep mind interim analys design higher bar
success continu remain confid rux potenti sr-cgvhd primari endpoint
orr rux vs bat includ bat addit imatinib
ibrutinib seven cycl treatment day result trial expect
upcom parsaclisib combin trial rux tafasitamab piqu interest
parsaclisib incyt inhibitor show signific reduct spleen volum qd
dose combin bid dose rux figur pivot trial test combin
mf patient current prepar initi data on-going phase ii trial
expect detail view evolv myelofibrosi treatment
landscap includ combin rux see note recent kol call conduct
addit part recent collabor licens agreement morphosi see
note respons initi combin trial tafasitamab plu parsaclisib r/r nhl
cll dose-escal dose expans trial expect begin year
excit see trial pan given impress result seen tafasitamab plu
idelalisib inhibitor like parsaclisib cosmo trial although r/r cll patient
treat trial achiev complet respons cr achiev partial respons
pr total overal respons rate orr
financi result report revenu increas
beat consensu estim estim
figur non-gaap consensu estim
non-gaap sg lower consensu estim
increas due continu progress compani
pipelin partial off-set decis longer co-fund develop baricitinib
eli lilli higher revenu lower expens compani report non-
gaap ep dilut higher consensu higher estim
compani end approxim cash cash equival market
report revenu increas beat consensu
estim estim figur non-gaap
line consensu estim within guidanc non-gaap sg
lower estim lower consensu non-
sg slightli lower guidanc higher revenu lower expens
compani report non-gaap ep dilut higher consensu higher
estim
guidanc provid guidanc includ impress jakafi revenu estim
 figur adjust annual price jakafi model reflect
recent price avail slightli decreas sg estim new
estim line guidanc
figur jmp estim consensu vs actual perform report
figur jmp estim consensu vs actual perform report
figur guidanc updat jmp estim
actualjmp estimatesconsensu differ actual vs jmp differ actual vs consensusprevi expens net incom loss net incom loss ep -dilut ep estim prior guidanc guidancejmp estim incyt corpor
drugrightsstatusmarketmarket eumyelofibrosi polycythemia veramarket steroid-refractori acut gvhdphase chronic gvhdphase prepar combin parsaclisib myelofibrosisphas ii combin pim refractori myelofibrosisphas ii prepar combin bet refractori myelofibrosisphas ii prepar combin on-going primari endpoint met atop dermatitisphas mg mg japan mg rheumatoid arthritisphas system lupu erythematosusphas atop dermatitisphas ii/sever alopecia areataphas ii endometri cancerphas ii cell carcinomaphas ii cancerphas prepar arg calitheraphas i/ii focu combin solid gitr allianc agenusphas i/ii dose escal complet develop expect focu combin solid allianc agenusphas i/ii dose escal complet develop expect focu combin solid tumorsitacitinib nave chronic iihidraden supperativaphas ii mzl mclphase iiautoimmun hemolyt pim phase i/ii first-in-human data present move forward focu combin pim plu jak inhibit hematolog malignanciesnda submit novarti cmet amp/mut phase ii plan nda submiss egfr wt neg phase iihepatocellular carcinomaphas nda reviewcholangiocarcinomaphas ii cancerphas ii mpnphase ii phase i/iiaml ihepatocellular axl/mer phase isolid allianc agenu phase isolid inhibitor small molecul phase isolid allianc agenusphas dose-escalationsolid ii preparationfibrodysplasia ossifican progressivarux creambaricitinibruxolitinib novarti ex-u capmatinib cmet licens novarti novartis lilli royalti ra opt ad sle pemigatinib licens macrogen parsaclisib corpor
jakafi compani report jakafi revenu yoy increas beat
consensu estim compani report jakafi
revenu beat consensu estim slightli beat guidanc
guidanc estim jakafi sale could reach
jakavi novarti report jakavi revenu lead royalti
yoy increas novarti report jakavi revenu lead
royalti increas estim jakavi royalti
could grow
iclusig report sale iclusig lower consensu lower
estim report sale iclusig lower consensu
estim sale fell lower rang guidanc
guid iclusig sale
olumi report ex-u olumi revenu
translat royalti revenu yoy increas report
olumi sale ex-u lead royalti revenu
repres increas ex-u revenu driven increas volum
off-set unfavor foreign exchang rate lower price
price target includ predict revenu exist soon-to-be-approv product
approv product includ rux mf pv sr-agvhd royalti rux mf pv
ex-u royalti baricitinib ra ponatinib cll stand
model also includ risk-adjust revenu select product approv
high degre confid succeed potenti product rux sr-
cgvhd eu sr-agvhd eu pemigatinib cca eu tafasitamab
dlbcl cll
pt howev includ risk-adjust revenu program develop
view program potenti upsid investor consequ detail market potenti
rux cream mild-to-moder ad estim million address patient
eu view mild-to-moder ad market opportun figur due
competit space pfizer eucrisa believ rux cream could achiev peak
market penetr howev given posit result trial see note
ascrib po consequ estim could receiv peak risk-adjust
revenu notabl appear conserv estim given eucrisa earn
sale
figur rux cream mild moder ad market summari
report thousand total address patient popul us project annual wac us total address market opportun us total address patient popul eu project annual wac eu total address market opportun eu total market opportun us eu year market penetr achiev us project market penetr us probabl success us risk-adjust revenu us year market penetr achiev eu project market penetr eu probabl success eu risk-adjust revenu eu total risk-adjust revenu creamatop dermat mild incyt corpor
rux cream vitiligo address vitiligo market estim includ vitiligo
patient current seek treatment well estim patient eu
figur view conserv estim given discuss kol see note
suggest million vitiligo patient seek treatment significantli
like efficaci therapi approv given impress result
present eadv congress see note believ rux cream could therapi
consequ await phase true-v result expect ascrib po
achiev predict market penetr could achiev risk-adjust revenu
figur rux cream vitiligo market summari
report thousand total address patient popul us project annual wac us total address market opportun us total address patient popul eu project annual wac eu total address market opportun eu total market opportun us eu year market penetr achiev us project market penetr us probabl success us risk-adjust revenu us year market penetr achiev eu project market penetr eu probabl success eu risk-adjust revenu eu total risk-adjust revenu incyt corpor
pemigatinib cca bladder cancer although includ potenti revenu cca
current model exclud potenti much larger bladder cancer market estim
address cca patient eu estim order magnitud
bladder cancer patient eu figur mean cca
market opportun bladder cancer one adjust po cca
program advanc bladder cancer program therefor give po
compar market penetr competit bladder cancer therefor
ascrib lower peak penetr compar cca howev leav estim
peak risk-adjust revenu cca bladder cancer
figur pemigatinib cca bladder cancer market summari
capmatinib mutat nsclc estim nsclc patient
neg egfr neg posit limit market lead peak risk-
adjust revenu novarti use market penetr expect
major biomarker-enrich patient use capmatinib po use royalti
rate agreement specifi royalti lead go
go make break highlight novarti like seek approv ex-u market
would surpris capmatinib achiev blockbust statu consider higher
royalti flow
pemigatinib fgfr inhibitor cholangiobladdertot address patient popul annual wac address market opportun address patient popul annual wac address market opportun market opportun us cholangio bladder market opportunitiesyear market penetr achiev market penetr success revenu market penetr achiev market penetr success revenu revenu risk-adjust revenu corpor
potenti approv pemigatinib second-lin mutant cholangiocarcinoma
potenti report updat phase ii data pemigatinib bladder cancer
rux itacitinib franchis
potenti report proof-of-concept data rux plu combin mf
potenti report phase result trial
potenti initi phase trial rux plu combin mf
potenti report healthi volunt data once-a-day rux
potenti report result itacitinib phase studi sn-cgvhd
potenti report top-lin clinic trial result
potenti nda submiss rux cream ad
potenti present full trial result scientif meet
potenti report initi true-v clinic trial result
potenti submiss tafasitamab dlbcl
potenti approv tafasitamab dlbcl
potenti initi dose escal dose expans trial tafasitamab plu parsaclisib
r/r nhl cll
potenti approv capmatinib novarti nsclc c-met-mutation-posit
potenti report data parsaclisib fl mcl mzl
potenti report data metastat squamou carcinoma anal canal
potenti report initi data solid tumor
valu biotechnolog compani base blend discount earn per share revenu
multipl analysi first evalu univers profit biotechnolog compani deriv
revenu multipl rang ep multipl rang base compani trade bear
bull market end ascertain rang revenu multipl
earn per share multipl
appli price-to-earnings multipl probability-adjust earn per share approxim
discount period obtain fair valu per share appli
revenu multipl probability-adjust revenu discount
period obtain per share fair valu averag result two method
ad current cash per share million share deriv price target
round
figur blend discount earn per share revenu multipl analysi
revenu estim combin increas sale exist commerci
product ruxolitinib mf pv sr-agvhd ponatinib cml baricitinib ra
potenti sale product believ high likelihood approv pemigatinib cca
tafasitamab dlbcl cll ruxolitinib sr-cgvhd
base scenario includ potenti revenu rux cream sale mild-to-
moder ad vitiligo pemigatinib sale bladder cancer itacitinib sn-cgvhd
bull scenario adjust probabl success po program base
confid data seen far includ risk-adjust revenu key pipelin product
valuat figur result fair valu
bear scenario remov risk-adjust revenu itacitinib assum lower-than-
expect long-term jakafi sale base scenario fair valu
bullbasebearrux cream ad cream ad cream vitiligo cream vitiligo sr-cgvhd sr-agvhd sr-cgvhd ad ad cholangio uretheli cancer cholangio uretheli cancer sn-agvhd sn-cgvhd sn-agvhd sn-cgvhd dlbcl dlbcl cll cll revenu mm dilut non-gaap ep success incyt corpor
figur chart incyt close price previou month price project
compani could achiev month bull base bear case scenario
revenu termin year revenu increas due higher-than-
anticip jakafi revenu incorpor recent jakafi price increas
expens increas cog sg expens proport increas jakafi
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad -- -- -- -- tafasitamab dlbcl cll pemigatinib cholangio uc total product revenu product royalti contract revenue- mileston revenue- total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term investments- interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor figur incom statement annual
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad tafasitamab dlbcl cll pemigatinib cholangio uc total product revenu product royalti contract revenue- mileston revenue- total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term investments- interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor incyt corpor
wilmington delaware-bas incyt corpor drug discoveri develop compani grow pipelin novel small-molecul
drug treat variou inflammatori disord cancer
risk invest thesi valuat includ clinic develop competit regulatori sector
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit program address lack
differenti clinic data drug and/or approv competit drug may advers impact sale potenti product
regulatori risk like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
sector risk valuat biotechnolog stock subject investor assess prospect underli compani investor
toler risk confid prospect biotechnolog stock group therefor stock price may fall even
compani meet exce investor expect
